Operating Income (Loss) of Alzamend Neuro, Inc. from 30 Apr 2020 to 31 Oct 2025

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
Alzamend Neuro, Inc. quarterly and annual Operating Income (Loss) in USD history and change rate from 30 Apr 2020 to 31 Oct 2025.
  • Alzamend Neuro, Inc. Operating Income (Loss) for the quarter ending 31 Oct 2025 was $998,109, a 27% increase year-over-year.
  • Alzamend Neuro, Inc. Operating Income (Loss) for the twelve months ending 31 Oct 2025 was $5,874,661, a 0.76% decline year-over-year.
  • Alzamend Neuro, Inc. annual Operating Income (Loss) for 2024 was $4,496,824, a 55% increase from 2023.
  • Alzamend Neuro, Inc. annual Operating Income (Loss) for 2023 was $9,937,645, a 33% increase from 2022.
  • Alzamend Neuro, Inc. annual Operating Income (Loss) for 2022 was $14,870,466, a 21% decline from 2021.
Source SEC data
View on sec.gov
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Change (%)
Operating Income (Loss), Annual (USD)
Operating Income (Loss), YoY Annual Change (%)

Alzamend Neuro, Inc. Quarterly Operating Income (Loss) (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $5,874,661 $998,109 +$359,959 +27% 01 Aug 2025 31 Oct 2025 10-Q 09 Dec 2025 2026 Q2
Q2 2025 $6,234,620 $2,700,201 -$1,737,796 -181% 01 May 2025 31 Jul 2025 10-Q 10 Sep 2025 2026 Q1
Q1 2025 $4,496,824 $1,138,936 -$288,874 -34% 01 Feb 2025 30 Apr 2025 10-K 22 Jul 2025 2025 FY
Q4 2024 $4,207,950 $1,037,415 +$1,622,515 +61% 01 Nov 2024 31 Jan 2025 10-Q 10 Mar 2025 2024 Q3
Q3 2024 $5,830,465 $1,358,068 +$1,543,654 +53% 01 Aug 2024 31 Oct 2024 10-Q 09 Dec 2025 2026 Q2
Q2 2024 $7,374,119 $962,405 +$2,563,526 +73% 01 May 2024 31 Jul 2024 10-Q 10 Sep 2025 2026 Q1
Q1 2024 $9,937,645 $850,062 +$2,454,947 +74% 01 Feb 2024 30 Apr 2024 10-K 22 Jul 2025 2025 FY
Q4 2023 $12,392,592 $2,659,930 +$2,763,582 +51% 01 Nov 2023 31 Jan 2024 10-Q 10 Mar 2025 2024 Q3
Q3 2023 $15,156,174 $2,901,722 +$204,681 +6.6% 01 Aug 2023 31 Oct 2023 10-Q 11 Dec 2024 2024 Q2
Q2 2023 $15,360,855 $3,525,931 -$490,389 -16% 01 May 2023 31 Jul 2023 10-Q 11 Sep 2024 2024 Q1
Q1 2023 $14,870,466 $3,305,009 +$567,787 +15% 01 Feb 2023 30 Apr 2023 10-K 30 Jul 2024 2024 FY
Q4 2022 $15,438,253 $5,423,512 -$2,866,946 -112% 01 Nov 2022 31 Jan 2023 10-Q 25 Mar 2024 2024 Q3
Q3 2022 $12,571,307 $3,106,403 +$477,531 +13% 01 Aug 2022 31 Oct 2022 10-Q 15 Dec 2023 2024 Q2
Q2 2022 $13,048,838 $3,035,542 -$729,303 -32% 01 May 2022 31 Jul 2022 10-Q 13 Sep 2023 2024 Q1
Q1 2022 $12,319,535 $3,872,796 -$2,652,820 -217% 01 Feb 2022 30 Apr 2022 10-K 27 Jul 2023 2023 FY
Q4 2021 $9,666,715 $2,556,566 -$1,440,907 -129% 01 Nov 2021 31 Jan 2022 10-Q 15 Mar 2023 2023 Q3
Q3 2021 $8,225,808 $3,583,934 -$2,285,988 -176% 01 Aug 2021 31 Oct 2021 10-Q 12 Dec 2022 2022 Q2
Q2 2021 $5,939,820 $2,306,239 -$987,932 -75% 01 May 2021 31 Jul 2021 10-Q 13 Sep 2022 2022 Q1
Q1 2021 $4,951,888 $1,219,976 01 Feb 2021 30 Apr 2021 10-K 19 Jul 2022 2022 FY
Q4 2020 $1,115,659 01 Nov 2020 31 Jan 2021 10-Q 15 Mar 2022 2022 Q3
Q3 2020 $1,297,946 01 Aug 2020 31 Oct 2020 10-Q 13 Dec 2021 2022 Q2
Q2 2020 $1,318,307 01 May 2020 31 Jul 2020 10-Q 13 Sep 2021 2022 Q1

Alzamend Neuro, Inc. Annual Operating Income (Loss) (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $4,496,824 +$5,440,821 +55% 01 May 2024 30 Apr 2025 10-K 22 Jul 2025 2025 FY
2023 $9,937,645 +$4,932,821 +33% 01 May 2023 30 Apr 2024 10-K 22 Jul 2025 2025 FY
2022 $14,870,466 -$2,550,931 -21% 01 May 2022 30 Apr 2023 10-K 30 Jul 2024 2024 FY
2021 $12,319,535 -$7,367,647 -149% 01 May 2021 30 Apr 2022 10-K 27 Jul 2023 2023 FY
2020 $4,951,888 -$527,727 -12% 01 May 2020 30 Apr 2021 10-K 19 Jul 2022 2022 FY
2019 $4,424,161 01 May 2019 30 Apr 2020 10-K 29 Jul 2021 2021 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.